Topical Antiandrogen

A new topical antiandrogen showed promise in a small, limited trial.

Acne vulgaris results from poral occlusion, lipolysis by Pityrosporum acnes, follicular rupture, and the influence of androgenic steroids on sebaceous glands. Systemically administered antiandrogenic drugs improve acne by antagonizing the action of androgenic steroids. To evaluate the benefit of topical antiandrogen treatment of acne vulgaris, investigators enrolled 77 adult men with grade 2 to 3 acne vulgaris in a clinical, randomized, double-blind comparison of the antiandrogen cortexolone 17α-propionate (C17P) with tretinoin and with placebo. Thirty patients were randomized to receive drug, 32 to receive the retinoid tretinoin 0.05% cream, and 15 to receive placebo cream. Each formulation was applied once daily at bedtime for 8 weeks. Ev…

Reviewing Author

Mark V. Dahl, MD

Disclosures

Consultant / Advisory board Ulthera, Inc.; AuBio LifeSciences, LLC; Paris Therapeutics

Equity Elorac, Inc.; Makucell, Inc.; Paris Therapeutics

Editorial boards UpToDate

Leadership positions in professional societiesNational Rosacea Society (Chairman, Medical Board)

Mark V. Dahl, MD

Disclosures

Consultant / Advisory board Ulthera, Inc.; AuBio LifeSciences, LLC; Paris Therapeutics

Equity Elorac, Inc.; Makucell, Inc.; Paris Therapeutics

Editorial boards UpToDate

Leadership positions in professional societiesNational Rosacea Society (Chairman, Medical Board)